Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 |
| Operating income | -$8.86M | -$9.60M | -$9.33M | -$8.66M | -$8.00M | -$8.74M | -$8.11M | -$8.94M | -$8.52M | -$9.59M |
| Net income | -$10.7M | -$10.3M | -$8.56M | -$8.42M | -$13.4M | -$8.82M | -$8.11M | -$8.59M | -$8.29M | -$9.47M |
| EPS (diluted) | -$0.19 | -$0.17 | -$0.13 | -$2.35 | -$2.39 | -$0.81 | -$0.70 | -$0.74 | -$0.70 | -$0.63 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.83M | -$7.90M | -$7.78M | -$6.80M | -$6.67M | -$8.21M | -$5.89M | -$5.67M | -$6.32M | -$8.48M |
| Capital expenditures | $476K | $165K | $242K | $73.8K | $8.64K | $239K | $324K | $152K | $157K | $57.0K |
| Free cash flow | -$7.31M | -$8.06M | -$8.02M | -$6.88M | -$6.67M | -$8.45M | -$6.22M | -$5.82M | -$6.47M | -$8.54M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24.2M | $15.1M | $7.08M | $2.56M | $13.7M | $20.5M | $14.1M | $8.15M | $4.80M | $1.56M |
| Total assets | $36.6M | $27.0M | $18.5M | $13.4M | $23.9M | $30.3M | $23.5M | $16.9M | $12.8M | $8.82M |
| Total liabilities | $13.6M | $6.68M | $882K | — | — | — | $413K | $2.03M | $1.36M | $1.30M |
| Long-term debt | — | $4.73M | $4.73M | — | — | — | — | — | — | — |
| Shareholders' equity | $23.0M | $20.3M | $17.7M | $10.6M | $21.8M | $29.9M | $23.1M | $14.9M | $11.5M | $7.52M |
| Retained earnings | -$64.8M | -$75.1M | -$83.7M | -$92.1M | -$106M | -$114M | -$122M | -$131M | -$139M | -$149M |
| Shares (wtd avg diluted) | 57.7M | 60.1M | 64.9M | 3.84M | 9.08M | 10.9M | 11.5M | 11.6M | 11.9M | 15.1M |
Every figure is extracted from NANOVIRICIDES, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.